BGOG-ov94/MAESTRA 1

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression 

Open
Trial drug
INCB123667
Grade
High grade
Prior lines
1, 2, 3, 4
Histology
Serous
Platin
Platinum resistant
Phase
II

Treatment

The treatment option in this study is INCB123667.
INCB123667 is taken orally.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.